A Study of Nivolumab and Ipilimumab and Nivolumab Alone in Combination With Trans-arterial ChemoEmbolization (TACE) in Participants With Intermediate Stage Liver Cancer — CheckMate 74W

Cancer, Hepatocellular Clinical Trial

Official title:
A Randomized, Multi-center, Double-blinded, Placebo-controlled Phase 3 Study of Nivolumab and Ipilimumab, Nivolumab Monotherapy, or Placebo in Combination With Trans-arterial ChemoEmbolization (TACE) in Patients With Intermediate-stage Hepatocellular Carcinoma (HCC)

Status Terminated

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of nivolumab with and without ipilimumab in combination with Trans-arterial ChemoEmbolization (TACE) to TACE alone in participants with intermediate liver cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04340193
Study type	Interventional
Source	Bristol-Myers Squibb
Contact
Status	Terminated
Phase	Phase 3
Start date	September 15, 2020
Completion date	December 12, 2023

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06144827` - A Pilot Study For Patients Receiving Radiation Therapy for Liver Cancer	N/A
Terminated	`NCT00669136` - Immunization With AFP + GM CSF Plasmid Prime and AFP Adenoviral Vector Boost in Patients With Hepatocellular Carcinoma	Phase 1
Completed	`NCT01929902` - Evaluation of Efficacy and Accuracy of Aquamantys Device in General Surgery
Completed	`NCT03586050` - Study to Evaluate the Safety and Effectiveness of Microwave Ablation in Patients With Hepatocellular Carcinoma in Korea	N/A